Immunocore Holdings plc

Greetings and welcome to the Immunocore Conference Calling Webcast. At this time, all participants are in listen-only mode. A question and answer session will follow the formal presentation. You may be placed into question queue at any time by pressing star 1 on your telephone keypad. We ask that you please limit yourselves to one question, then return to the queue. As a reminder, this conference is being recorded. If anyone should require operator assistance, please press star 0. It's now my pleasure to turn the call over to Ryan Baker, Vice President, Investor Relations. Ryan, please go ahead.

Good morning and good afternoon. Thank you for joining us on our Q2 and first half 2026 earnings call. During today's call, we will make some forward-looking statements which are qualified by our safe harbor provision under the Private Securities Litigation Reform Act of 1995. Please note that actual results can vary materially from those indicated by these forward-looking statements. including those discussed in our filings with the SEC. On today's call, I am joined by Dr. Bahija Jallal, CEO of Immunocore, who will share achievements from the first half of 2026. Ralph Torbay, Chief Commercial Officer, will review our Q2 first half chem track results and recently published five-year overall survival data. Dr. Mohammad Dar, our Chief Medical Officer, will provide a pipeline update and Travis Coy, Our CFO and head of corporate development will provide some key highlights from our financial results reported earlier this morning. I will now turn the call over to Dr. Bahija Jallal.

Good morning and good afternoon, and thank you for joining us today. Before I start, I would like to welcome Ryan Baker, who joined us last week as our new vice president of investor relations. So welcome, Ryan. Guided by our missions, We have continued to execute as planned across the business. We remain focused on our three strategic priorities, maximizing the value of chemtraq, advancing our melanoma portfolio, and expanding into other tumor types, and realizing opportunities in infection and autoimmune diseases. Starting with KimTrack, we generated $223 million in net revenue in the first half of the year, representing 16% growth compared to the first half of 2025. At ASCR in April, we presented the five-year overall survival data that showed that KimTrack doubles the likelihood of being alive at five years for patients with HLA-A2 positive metastatic uveal melanoma. For a disease once measured in months, five years is extraordinary. And some of those patients are alive today because of this medicine. This is why we come to work every day. In melanoma, we are advancing three ongoing phase three trials, TEBI-AM, ATOM, and PRISML-301. An important differentiator for a company of our size. Beyond melanoma, we expect to present updated PRAME data in additional tumor types by the end of the year and to provide initial P-WELL data in 2027. In autoimmune diseases, the first patient is to be dosed with our first autoimmune candidates in type 1 diabetes in the coming weeks. We also remain on track to submit the CTA for our second autoimmune candidates by the end of 2026. Finally, in HIV, we have completed enrollment of additional patients at higher dose cohorts up to 1.2 mgs as part of the multiple ascending dose part of the Phase 1-2 trial. We are analyzing the new data and plan to share results early next year. Overall, we are continuing to execute across our commercial portfolio and pipeline with multiple opportunities to create value for patients and shareholders. And now ask Ralph to share details about our commercial performance. Ralph?